Search research articles
Contact Us
Filters
Showing results (31-40 of 311) with videos related to
Page
of 32
Sort By:
Prostate Cancer and Prostatic Diseases
|
December 8, 2023
High-risk biochemical recurrence of locally treated prostate cancer after EMBARK. An end to decades of conventional wisdom?
Vérane Achard, Bertrand Tombal
European Urology
|
June 13, 2024
All Biochemical Recurrences Are Equal, but Some Are More Equal than Others
Verane Achard, Bertrand Tombal
European Urology Oncology
|
February 6, 2025
Reply to Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, and Alberto Briganti's Letter to the Editor re: Bertrand F. Tombal, Francisco Gomez-Veiga, Alvaro Gomez-Ferrer, et al. A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532). Eur Urol Oncol 2024;7:1051-60
Bertrand Tombal, Yohann Loriot
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 6, 2024
Systemic Treatment for Biochemical Recurrence of Localized Prostate Cancer: Do Not EMBARK on When, If the Answer Is How
Bertrand Tombal, Gianluca Giannarini
European Urology
|
October 22, 2008
Open to debate. The motion: Hormonal blockade should be limited due to significant adverse effects
Laurent Boccon-Gibod, Bertrand Tombal
The New England Journal of Medicine
|
October 30, 2014
Enzalutamide in metastatic prostate cancer before chemotherapy
Tomasz M Beer, Bertrand Tombal
BJU International
|
March 1, 2013
Landmarks in hormonal therapy for prostate cancer
Bertrand Tombal, E David Crawford
Cancer Management and Research
|
March 31, 2011
Cardiovascular risk during hormonal treatment in patients with prostate cancer
Hein Van Poppel, Bertrand Tombal
Cancer Management and Research
|
June 2, 2011
Chemoprevention of prostate cancer with nutrients and supplements
Hendrik Van Poppel, Bertrand Tombal
European Urology Open Science
|
February 3, 2026
Re: Amar U. Kishan, Luca F. Valle, Holly Wilhalme, et al. <sup>177</sup>Lu-Prostate-specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-label, Randomized, Controlled, Phase II Study. J Clin Oncol 2025;43:3812-21
Vérane Achard, Thomas Zilli, Bertrand Tombal
Page
of 32
Search research articles
Search
Showing results (31-40 of 311) with videos related to
Sort By:
Page
of 32
Prostate Cancer and Prostatic Diseases
|
December 8, 2023
High-risk biochemical recurrence of locally treated prostate cancer after EMBARK. An end to decades of conventional wisdom?
Vérane Achard, Bertrand Tombal
European Urology
|
June 13, 2024
All Biochemical Recurrences Are Equal, but Some Are More Equal than Others
Verane Achard, Bertrand Tombal
European Urology Oncology
|
February 6, 2025
Reply to Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, and Alberto Briganti's Letter to the Editor re: Bertrand F. Tombal, Francisco Gomez-Veiga, Alvaro Gomez-Ferrer, et al. A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532). Eur Urol Oncol 2024;7:1051-60
Bertrand Tombal, Yohann Loriot
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 6, 2024
Systemic Treatment for Biochemical Recurrence of Localized Prostate Cancer: Do Not EMBARK on When, If the Answer Is How
Bertrand Tombal, Gianluca Giannarini
European Urology
|
October 22, 2008
Open to debate. The motion: Hormonal blockade should be limited due to significant adverse effects
Laurent Boccon-Gibod, Bertrand Tombal
The New England Journal of Medicine
|
October 30, 2014
Enzalutamide in metastatic prostate cancer before chemotherapy
Tomasz M Beer, Bertrand Tombal
BJU International
|
March 1, 2013
Landmarks in hormonal therapy for prostate cancer
Bertrand Tombal, E David Crawford
Cancer Management and Research
|
March 31, 2011
Cardiovascular risk during hormonal treatment in patients with prostate cancer
Hein Van Poppel, Bertrand Tombal
Cancer Management and Research
|
June 2, 2011
Chemoprevention of prostate cancer with nutrients and supplements
Hendrik Van Poppel, Bertrand Tombal
European Urology Open Science
|
February 3, 2026
Re: Amar U. Kishan, Luca F. Valle, Holly Wilhalme, et al. <sup>177</sup>Lu-Prostate-specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-label, Randomized, Controlled, Phase II Study. J Clin Oncol 2025;43:3812-21
Vérane Achard, Thomas Zilli, Bertrand Tombal
Page
of 32